drugset / Trial / NCT04539639
Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Jaktinib in participants with moderate to severe atopic dermatitis.
Timeline
- Start
- 2020-12-02
- Primary completion
- 2022-05-19
- Completion
- 2022-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Jaktinib | Unknown | 50 mg | — |
| Subject | Jaktinib | Unknown | 75 mg | — |
| Subject | Jaktinib | Unknown | 100 mg | — |